Incyte Corp. (INCY) Company Profile & Statistics

Incyte Corp.
INCY
(Nasdaq - US)
Closed
70.38
-0.67 (-0.94%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
71.46
High
71.46
Low
69.32

About Incyte Corp.

CEO

Herv¿ Hoppenot

Headquarters

1801 augustine cut-off

wilmington, de 19803, united states

Auditor

Ernst & Young LLP

Employees

2,524

Share Holders

112

Website

www.incyte.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

Incyte Corp. Statistics

Valuation Measures

Market Capitalization ²	13.56B
Enterprise Value	12.29B
Enterprise Value/EBITDA (ttm)	347.08
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	4.29
Price to Sales (ttm)	3.34
Price to Cash (ytd)	28.98

Profitability

Gross Margin (ttm)	92.82%
Operating Margin (ttm)	-0.65%
Profit Margin (ttm)	1.46%
Return on Equity (ttm)	-0.63%
Return on Invested Capital (ttm)	-4.39%
Return on Assets (ttm)	-0.45%

Income Statement

Revenue (ttm)	4.08B
Revenue Per Share (ttm)	21.16
Gross Profit (ttm)	3.78B
EBITDA (ttm)³	35.40M
Net Income Avi to Common (ttm)	32.48M
Diluted EPS (ttm)	0.14

Share Statistics

Beta (5Y Monthly)	0.71
52-Week Change	28.64%
S&P500 52-Week Change	30.55%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	192.65M
Dividend Yield	0.00%
Float ⁴	158.74M
% Held by Insiders	17.60%
% Held by Institutions	96.97%

Balance Sheet

Total Cash (mrq)	1.77B
Total Cash Per Share (mrq)	9.21
Total Debt (mrq)	32.16M
Total Debt/Equity (mrq)	1.01%
Current Ratio (mrq)	1.87%
Quick Ratio (mrq)	1.82%
Book Value Per Share (mrq)	16.45

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.23
Free Cash Flow (ytd)	-114.76M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Incyte Corp.

Trade With A Regulated Broker